Showing results 1 to 5 of 5
| Title | Author(s) | Issue Date | Views | |
|---|---|---|---|---|
3-weekly Daratumumab-imid-dexamethasone Is Highly Efficacious And Cost-effective In Relapsed/refractory Multiple Myeloma Proceeding/Conference:The 17th International Myeloma Workshop, 2019 | 2019 | 4 | ||
3-weekly Daratumumab-IMiD-dexamethasone is highly efficacious, hence financially affordable with enormous economic impacy for relapsed/ refractory Multiple Myeloma in less affluent counties Proceeding/Conference:The 24th Congress of European Haematology Association (EHA) | 2019 | |||
| 2021 | ||||
Opioid therapy for chronic non-cancer pain: guidelines for Hong Kong Journal:Hong Kong Medical Journal | 2016 | 131 | ||
Review of Newly Registered Oncology Drugs in Hong Kong Journal:Hong Kong Pharmaceutical Journal | 2016 | 12 |